Trial: 202201087

An Open-Label, Multicenter Phase 1/2 Study of Surufatinib in Combination with Gemcitabine in Pediatric, Adolescent, and Young Adult Patients with Recurrent or Refractory Solid Tumors



Principal Investigator

Armstrong, Amy

Disease Site

Anus; Bones and Joints; Breast; Colon; Esophagus; Eye and Orbit; Hodgkin Lymphoma; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Lung; Non-Hodgkin Lymphoma; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Urinary Bladder

Learn more about this study at: